Provencio, M. http://orcid.org/0000-0002-2826-656X
Romero, N.
Tabernero, J.
Vera, R.
Baz, D. V.
Arraiza, A.
Camps, C.
Felip, E.
Garrido, P.
Gaspar, B.
Llombart, M.
López, A.
Magallón, I.
Ibáñez, V. M.
Olmos, J. M.
Mur, C.
Navarro-Ruiz, A.
Pastor, A.
Peiró, M.
Polo, J.
Rodríguez-Lescure, Á.
Funding for this research was provided by:
astrazeneca
Universidad Autónoma de Madrid
Article History
Received: 26 July 2021
Accepted: 11 August 2021
First Online: 29 October 2021
Declarations
:
: M Provencio reports grants, personal fees and non-financial support from BMS, grants, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from Astrazeneca, personal fees from MSD, personal fees from Takeda, outside the submitted work. J Tabernero reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech, Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics and TheraMyc. He declares institutional financial interest in form of financial support for clinical trials or contracted research for Amgen Inc, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc, Janssen-Cilag SA, Merck Sharp & Dohme, Novartis Farmacéutica SA, Taiho Pharma USA Inc, Pharma Mar, Spanish Association Against Cancer Scientific Foundation and Cancer Research UK. R Vera declares that she has no conflict of interest. A Arraiza declares that he has no conflict of interest. E Felip reports personal fees for speaking or attending advisory boards for: Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Glaxo Smith Kline, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Novartis, Peptomyc, Peervoice, Pfizer, Regeneron, Sanofi, Syneos Health, Seattle Genetics, Takeda, Touch Medical. She is an independent member of the board at GRÍFOLS. P Garrido declare personal financial interests: Abbvie, Advisory Role, Amgen, Advisory Role, AstraZeneca, Speaker, Advisory Role, Bayer, Advisory Role, Boehringer Ingelheim, Speaker, Advisory Role, Bristol (BMS), Speaker, Advisory Role, GlaxoSmithKline (GSK), Advisory Role, Janssen, Speaker, Advisory role, Lilly, Advisory Role, MSD, Speaker, Advisory Role, Novartis, Speaker, Advisory Role, Pfizer, Speaker, Advisory Role, Roche, Speaker, Advisory Role, Takeda, Advisory Role, Speaker, Spouse: BI, Speaker, Advisory Role, Gebro, Advisory Role, Janssen, Speaker, Advisory Role, Nordic, Advisory Role, Steering Committee: Janssen. A López declares that he has refused funding for this project. C Mur declares that he has no conflict of interest. A Navarro declares he has received fee for AstraZeneca. A Pastor declares that she has no conflict of interest. M Peiró declares that Astra Zeneca has made payments to ESADE, on behalf of the Institute for Healthcare Management, for the strategic direction of the ASISTO project. J Polo states that in the last 3 years he has received honoraria for presentations at national congresses in activities sponsored by Boehringer Ingelheim, Bayer, Daiichi-Sankyo. Pfizer—BMS, Menarini. Almirall Bial. Honoraria as author of multiple publications sponsored by Boehringer Ingelheim, Bayer, Pfizer—BMS, Novartis, Bial, Almirall. Fees as scientific committee of studies: Degree of control of ACO in Spain PAULA Study (funded by Bayer) ESCONDIDA Study (Pfizer—BMS) and SAMOA Study (Pfizer—BMS) Study of quality control of ACO in Spain funded by Boehringer Ingelheim. GLORIA AF study funded by Boehringer Ingelheim, PREFER study funded by Novartis, AGORA study funded by MSD. A Rodríguez-Lescure. COIs: Employment: None. Consultant or Advisory Role: Roche, Pfizer, Novartis, Lilly, MSD, AstraZeneca, Daiichi-Sankyo. Stock Ownership: None. Research Funding: To my Institution: Roche, Novartis, Pfizer, Lilly, AstraZeneca, Amgen, MSD, BMS, Zymeworks, GEICAM. o my person: None. Speaking: Roche, Pfizer, Novartis, Lilly, A-Z, MSD, Merck, Pierre- Fabré, Ipsen. Grant support: None Other: Travel, Accommodations (ASCO, SABCS): Roche, Pfizer.